Beyond Air Inc (NASDAQ:XAIR), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, stock fell 24.39% (As on June 18, 11:31:42 AM UTC-4, Source: Google Finance) after the company reported a narrower-than-expected loss for its fiscal fourth quarter and provided strong revenue guidance for the current year. For the full fiscal year 2025, Beyond Air’s revenue jumped 220% to $3.7 million compared to $1.2 million in fiscal 2024, driven by growing demand for its LungFit PH nitric oxide delivery system. The company recently submitted a PMA supplement to the FDA for its second-generation LungFit PH device, which Lisi said “could be transformative for our business” if approved. Beyond Air has ended the quarter with $6.9 million in cash and marketable securities, which excludes the $1.0 million payment from GETZ Healthcare that arrived after March 31, 2025, and total long-term debt outstanding of $12.2 million.
Further, the company has established a partnership with Vanderbilt University Medical Center (VUMC) as the first luminary site for LungFit PH, marking a major milestone in Beyond Air’s mission to redefine tankless nitric oxide (iNO) delivery and drive continued innovation in respiratory care. The company has commenced international shipments of LungFit PH following new regulatory approvals and distribution agreements, supporting the Company’s global expansion across Europe, the Middle East and Asia. Over the past few months, the Company secured several new distribution partnerships in India, Italy, Latvia, Lithuania, Estonia, Ukraine, Kuwait, Kazakhstan, Israel and Poland. As a result, the Company has more than 25 countries covered under distribution agreements, covering more than 2 billion lives.
XAIR in the fourth quarter of FY25 has reported the adjusted loss per share of 9 cents, beating the analysts’ estimates for the adjusted loss per share of 14 cents, according to the Zacks Consensus Estimate. The company had reported the adjusted revenue of $1.15 million in the fourth quarter of FY25, missing the analysts’ estimates for revenue by 17.12%.
Looking ahead, the company expects revenue of at least $1.7 million for the current quarter ending June 30, representing over 45% sequential growth. For fiscal 2026, Beyond Air guided for revenue between $12 million to $16 million. Regulatory approvals and new international partnerships across Europe, the Middle East, and Asia have already driven strong order activity, with over a dozen initial units shipped to customers in just the past few weeks.